Pfizer opens new precision drug center; Fate strikes pact for NK cancer drug development;

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: $CELG chief Bob Hugin isn't done betting on 'binary' biotech deals--"we're going to go after them at the right time." Report | Follow @JohnCFierce

@DamianFierce: Here's the $CELG + $RCPT release. PR/Story | Follow @DamianFierce

> Pfizer ($PFE) debuted its Center of Excellence in Precision Medicine in Santiago, Chile, last week, bulking up in Latin America, which is not exactly a hot spot for pharma industry R&D. Story

> Fate Therapeutics ($FATE) has struck a deal to collaborate with the University of Minnesota for the development of natural killer (NK) cell-based cancer immunotherapeutics. Release

Medical Device News

@FierceMedDev: Swedish biotech ropes in $11M for automated HIV testing device. FierceDiagnostics item | Follow @FierceMedDev

@VarunSaxena2: ICYMI: India moving closer to implementing price controls on medical devices. Story | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Noninvasive prenatal tests can pinpoint cancer in mothers. Story | Follow @EmilyWFierce

> U.K. researchers develop noninvasive, infrared-based blood glucose monitor, license it to startup. More

> Breakout Dx player Theranos keys into Medicaid with latest deal in managed care. Article

Pharma News

@FiercePharma: Almac's launch of Singapore APAC HQ also eyes regional growth of small biotechs. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Why did FDA ban Emcure India plant? Recall of drugs manufactured for Teva may provide a clue. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AZ's Iressa gets back in the game with first-line FDA approval in lung cancer. Report | Follow @CarlyHFierce

> J&J set to reopen McNeil plant amid consumer biz overhaul. Article

> Sanofi CEO revamps operations, tapping chiefs for 3 new units. More

Pharma Marketing News

> J&J chief touts $1B-plus prospects for coming psoriasis med guselkumab. More

> Dr. Reddy's spruces up corporate branding for U.S. marketing assault. Item

> Roche's atezo lines up PD-L1 data for forthcoming battle with Keytruda, Opdivo. Story

> Two agency giants duke it out for GlaxoSmithKline $900M media account. Report

> Programmatic's the latest word for targeting drug pitches to the right docs. Article

Biotech Research News

> Peptide shells provide a targeted cancer drug delivery system. Item

> Caspase-1 molecule highlighted as key player in regulating vascular ischemia. More

> Johns Hopkins team points to a new therapeutic approach to hearing loss. Report

> Penn study confirms a link between male infertility and genetic mutations. Story

> Nonviral gene therapy shrinks brain tumors in rats. Article

Diagnostics News

> Merck invests $6M in microbial diagnostics specialist OpGen. Report

> Qiagen scores FDA approval for lung cancer companion Dx. News

> Xagenic reels in $15M for point-of-care testing system. Story

> Natera joins forces with University College London for lung cancer study. Article

> CombiMatrix coasts toward growth with renewed sales push. Editor's corner